Phase III study of sunitinib malate (SU11248) versus interferon-α as first-line treatment in patients with metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 5, Issue 1, 2006, Pages 23-25

  Reddy, Kesava ^a   Bukowski, Ronald M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LACTATE DEHYDROGENASE; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; THROMBOCYTOPENIA; TREATMENT OUTCOME; COMPARATIVE STUDY; KIDNEY TUMOR; METASTASIS; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; PYRROLES; RANDOMIZED CONTROLLED TRIALS;

EID: 33749052312     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1558-7673(11)70151-3     Document Type: Article

References (11)

1. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-3605.
2. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006; 5:1280-1289.
3. FDA Approves New Treatment for Gastrointestinal and Kidney Cancer [press release]. Washington, DC: US Food and Drug Administration; January 26, 2006. Available at: http://www.fda.gov/bbs/topics/news/2006/ new01302.html. Accessed June 28, 2006.
4. Clinical Trials.gov [Web site]. An explorative study of tolerability and pharmacokinetics of SU011248 in combination with docetaxel as first-line treatment in patients with breast cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00291577?order=14. Accessed June 28, 2006.
5. Clinical Trials.gov [Web site]. Phase 2 study of SU011248 as consolidation therapy in patients with locally advanced or metastatic non-small cell lung cancer. Available at: http://www.clinicaltrials.gov/ ct/show/NCT00113516?order=11. Accessed June 28, 2006.
6. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63:4009-4016.
7. Raymond E, Faivre S, Vera C, et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003; 22:192.
8. Rosen L, Mulay M, Long J, et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:191.
9. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU111248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006: 24:16-24.
10. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcino ma. JAMA 2006; 295:2516-2524.
11. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Presented at: The 42nd Annual Meeting of the American Society of Clinical Oncology: June 4-6, 2006; Atlanta, GA.